What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?

Current Cardiology Reports

Volumn 13, Issue 6, 2011, Pages 520-526

  Sica, Domenic A ^a,b  

^a MCV Box 980341   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Eplerenone; Hyperkalemia; Primary aldosteronism; Resistant hypertension; Spironolactone

Indexed keywords

ALDOSTERONE; EPLERENONE; SPIRONOLACTONE;

ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENDOCRINE FUNCTION TEST; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; MASTALGIA; PRIMARY HYPERALDOSTERONISM; SALT LOADING; TREATMENT OUTCOME;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERKALEMIA; HYPERTENSION; MALE; PRACTICE GUIDELINES AS TOPIC; SPIRONOLACTONE;

EID: 81255185026     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0224-z     Document Type: Article

References (48)

1. DA Calhoun D Jones S Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 1403 1419 18391085 10.1161/HYPERTENSIONAHA. 108.189141 1:CAS:528:DC%2BD1cXlvFaitLw%3D This is a superb and comprehensive overview on the topic of resistant hypertension.
2. PA Sarafidis GL Bakris 2008 Resistant hypertension: an overview of evaluation and treatment J Am Coll Cardiol 52 1749 1757 19022154 10.1016/j.jacc.2008.08.036
3. J Václavík R Sedlák M Plachy K Navrátil J Plásek J Jarkovsky, et al. 2011 Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial Hypertension 57 1069 1075 21536989 10.1161/ HYPERTENSIONAHA.111.169961
4. M Engbaek M Hjerrild J Hallas IA Jacobsen 2010 The effect of low-dose spironolactone on resistant hypertension J Am Soc Hypertens 4 290 294 21130975 10.1016/j.jash.2010.10.001
5. PM Jansen AH Jan AH Danser BP Imholz AH van der Meiracker 2009 Aldosterone-receptor antagonism in hypertension J Hypertens 27 680 691 19516169 10.1097/HJH.0b013e32832810ed 1:CAS:528:DC%2BD1MXjtlOltbw%3D
6. JC Marrs 2010 Spironolactone management of resistant hypertension Ann Pharmacother 44 1762 1769 20978214 10.1345/aph.1P338 1:CAS:528: DC%2BC3cXhsVynsr7F
7. J Batterink SN Stabler AM Tejani CT Fowkes 2010 Spironolactone for hypertension Cochrane Database Syst Rev 4 8 CD008169
8. SD Persell 2011 Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 1076 1080 21502568 10.1161/HYPERTENSIONAHA. 111.170308 1:CAS:528:DC%2BC3MXmt1GhtL4%3D
9. A de la Sierra J Segura JR Banegas M Gorostidi JJ de la Cruz P Armario, et al. 2011 Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring Hypertension 57 898 902 21444835 10.1161/HYPERTENSIONAHA.110.168948 This is a comprehensive study that determined the frequency of white-coat hypertension among a large population base with no resistant hypertensives
10. GP Rossi G Bernini C Caliumi G Desideri B Fabris C Ferri, et al. 2006 A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J Am Coll Cardiol 48 2293 2300 17161262 10.1016/j.jacc.2006.07.059 1:CAS:528:DC%2BD28Xht12ks7%2FK
11. S-C Tiu C-H Choi C-C Shek Y-W Ng FK Chan C-M Ng, et al. 2005 The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling J Clin Endocrinol Metab 90 72 78 15483077 10.1210/jc.2004-1149 1:CAS:528: DC%2BD2MXlvFemsQ%3D%3D
12. P Mulatero F Rabbia A Milan C Paglieri F Morellow L Chiandussi, et al. 2002 Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism Hypertension 40 897 902 12468576 10.1161/01.HYP.0000038478.59760. 41 1:CAS:528:DC%2BD38XovFKnsrw%3D
13. YH Lin SM Wang VC Wu JK Lee CC Kuo RF Yen, et al. 2011 The association of serum potassium level with left ventricular mass in patients with primary aldosteronism Eur J Clin Invest. 41 743 750 21250985 10.1111/j.1365-2362.2010. 02462.x 1:CAS:528:DC%2BC3MXpsVGlsrw%3D
14. AM Marney NJ Brown 2007 Aldosterone and end-organ damage Clin Sci (Lond) 113 267 278 10.1042/CS20070123 1:CAS:528:DC%2BD2sXovFGqtLo%3D
15. B Pitt F Zannad WJ Remme R Cody A Castaigne A Perez J Palensky, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 709 717 10471456 10.1056/ NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D
16. B Pitt W Remme F Zannad J Neaton F Martinez B Roniker, et al. 2003 Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 12668699 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D
17. F Zannad JJ McMurray H Krum DJ van Veldhuisen K Swedberg H Shi J Vincent, et al. 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
18. JP Bertocchio DG Warnock F Jaisser 2011 Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease Kidney Int 79 1051 1060 21412221 10.1038/ki.2011.48 1:CAS:528:DC%2BC3MXltlyjuro%3D
19. S Yagi M Akaike K Aihara T Iwase S Yoshida Y Sumitomo-Ueda, et al. 2011 High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension Hypertens Res 34 74 78 20861841 10.1038/hr.2010.179 1:CAS:528:DC%2BC3MXhs1KktQ%3D%3D
20. HK Parthasarathy K Alhashmi AD McMahon AD Struthers GT McInnes I Ford JM Connell, et al. 2010 Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO J Hypertens 28 170 177 20009770 10.1097/HJH.0b013e328332b79b 1:CAS:528: DC%2BD1MXhsFKgu7vK This paper characterizes the manner in which the relationship between the aldosterone and PRA ratio defines the response to diuretic therapy
21. WF Young 2007 Primary aldosteronism: renaissance of a syndrome Clin Endocrinol (Oxf) 66 607 618 10.1111/j.1365-2265.2007.02775.x 1:CAS:528:DC%2BD2sXlvFKlur8%3D
22. JW Funder RM Carey C Fardella CE Gomez-Sanchez F Mantero M Stowasser, et al. 2008 Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society practice guideline J Clin Endocrinol Metab 93 3266 3181 18552288 10.1210/jc.2008-0104 1:CAS:528:DC%2BD1cXhtFChurrI This paper discusses the preeminent guidelines on case detection, diagnosis, and treatment of patients with primary aldosteronism. It offers an excellent description of workup components and treatment stratagems
23. C Seifarth S Trenkel H Schobel EG Hahn J Hensen 2002 Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism Clin Endocrinol 57 457 465 10.1046/j.1365-2265.2002.01613.x 1:CAS:528: DC%2BD38XotlGgsb0%3D
24. WF Young Jr MJ Hogan GG Klee CS Grant JA Van Heerden 1990 Primary aldosteronism; diagnosis and treatment Mayo Clin Proc 65 96 110 2404167
25. EL Bravo RC Tarazi HO Dustan FK Fouad SC Textor RW Gifford, et al. 1983 The changing clinical spectrum of primary aldosteronism Amer J Med 74 641 651 6340491 10.1016/0002-9343(83)91022-7 1:STN:280:DyaL3s7nsFKqtg%3D%3D
26. PO Lim CA Farquharson P Shiels RT Jung AD Struthers TM MacDonald 2001 Adverse cardiac effects of salt with fludrocortisone in hypertension Hypertension 37 856 861 11244008 1:CAS:528:DC%2BD3MXitFegtLg%3D
27. RD Gordon M Stowasser JC Rutherford 2001 Primary aldosteronism: are we diagnosing and operating on too few patients? World J Surg 25 941 947 11572036 10.1007/s00268-001-0033-4 1:STN:280:DC%2BD3MrisVGitA%3D%3D
28. FE Nwariaku BS Miller R Auchus S Holt L Watumull B Dolmatch S Nesbitt, et al. 2006 Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome Arch Surg 141 497 502 16702522 10.1001/archsurg.141.5.497
29. HK Parthasarathy J Menard WB White WF Young Jr GH Williams B Williams, et al. 2011 A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and primary aldosteronism J Hypertens 29 980 990 21451421 10.1097/HJH.0b013e3283455ca5 1:CAS:528:DC%2BC3MXktl2gsLk%3D This is the first study to carefully evaluate two different MRAs in the treatment of hypertension and primary aldosteronism
30. MH Weinberger WB White LM Ruilope TM MacDonald RC Davidson B Roniker, et al. 2005 Effects of eplerenone versus losartan in patients with low-renin hypertension Am Heart J 150 426 433 16169319 10.1016/j.ahj.2004.12.005 1:CAS:528:DC%2BD2MXhtVWgtrnM
31. A Mahmud M Mahgoub M Hall J Feely 2005 Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens 18 1631 1635 16364838 10.1016/j.amjhyper.2005.06. 010 1:CAS:528:DC%2BD2MXhtlCrs7nN
32. HK Parthasarathy K Alhashmi AD McMahon, et al. 2010 Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO J Hypertens 28 170 177 20009770 10.1097/HJH.0b013e328332b79b 1:CAS:528:DC%2BD1MXhsFKgu7vK
33. DL Murdoch G Forrest DL Davies GT McInnes 1993 A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects Br J Clin Pharmacol 35 373 378 8485017 1:CAS:528:DyaK3sXisVOhu7w%3D
34. T Dyckner PO Wester L Widman 1986 Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension Eur J Clin Pharmacol 30 535 540 3758141 10.1007/BF00542411 1:STN:280:DyaL2s%2FgsVyjuw%3D%3D
35. HB Slim HR Black PD Thompson 2011 Older blood pressure medications-do they still have a place? Am J Cardiol 108 308 316 21550576 10.1016/j.amjcard. 2011.03.041 1:CAS:528:DC%2BC3MXotl2gsLw%3D
36. F de Souza E Muxfeldt R Fiszman G Salles 2010 Efficacy of spironolactone therapy in patients with true resistant hypertension Hypertension 55 147 152 19858405 10.1161/HYPERTENSIONAHA.109.140988
37. DA Lane S Shah DG Beevers 2007 Low-dose spironolactone in the management of resistant hypertension: a surveillance study J Hypertens 25 891 894 17351384 10.1097/HJH.0b013e328014954d 1:CAS:528:DC%2BD2sXislSrtrg%3D
38. N Chapman J Dobson Wilson Sarah, et al. 2007 Effect of spironolactone on blood pressure in patients with resistant hypertension Hypertension 49 839 845 17309946 10.1161/01.HYP.0000259805.18468.8c 1:CAS:528:DC%2BD2sXivVamt78%3D
39. B Alvarez-Alvarez M Abad-Cardiel A Fernandez-Cruz N Martell-Claros 2010 Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system J Hypertens 28 2329 2335 20651602 10.1097/HJH.0b013e32833d4c99 1:CAS:528:DC%2BC3cXht1yktb%2FO
40. A Ludbrook M Dynon FA Mendelsohn WJ Louis 1980 Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension Med J Aust 1 124 125 6990208 1:STN:280:DyaL3c7oslKgsg%3D%3D
41. GM Bell L Fananapazir JL Anderton 1981 Comparison of single and divided daily dose spironolactone in the control of hypertension Br J Clin Pharmacol 12 585 588 7295494 1:STN:280:DyaL38%2Fks1WrsQ%3D%3D
42. MH Weinberger B Roniker SL Krause RJ Weiss 2002 Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am J Hypertens 15 709 716 12160194 10.1016/S0895-7061(02)02957-6 1:CAS:528:DC%2BD38Xms1aisLw%3D
43. FA Akbar PF Boston J Chapman MY Pearce 1981 Spironolactone and hydroflumethiazide in the treatment of hypertension Br J Clin Pract 35 317 321 7034762 1:STN:280:DyaL387htlCkuw%3D%3D
44. LI Rose RH Underwood SR Newmark ES Kisch GH Williams 1977 Pathophysiology of spironolactone-induced gynecomastia Ann Intern Med 87 398 403 907238 1:CAS:528:DyaE1cXjt1Cgsw%3D%3D
45. G Dimitriadis V Papadopoulos K Mimidis 2011 Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics Hepatol Int 5 738 739 21484105 10.1007/s12072-010-9235-x
46. DA Sica M Hess 2004 Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure Congest Heart Fail 10 259 264 15470306 10.1111/j.1527-5299.2004.02814.x 1:CAS:528:DC%2BD2cXpsFShsbc%3D
47. DA Sica 2005 Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis Heart Fail Rev 10 23 29 15947888 10.1007/s10741-005-2345-1 1:CAS:528:DC%2BD2MXltFGqsr0%3D
48. DA Sica 2009 Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not Hypertension 53 749 750 19307465 10.1161/HYPERTENSIONAHA.108.128017 1:CAS:528:DC%2BD1MXls1Sktrk%3D